Maze (MAZE)
Develops small-molecule therapies guided by human genetics for kidney and metabolic diseases.
$26.70
At close+0.17 (+0.64%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.79
Revenue estimate
$333.3K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$1.15−$0.77−$0.66−$0.65−$0.45−$0.76−$0.76Pending
Estimate−$0.76−$0.79−$0.74−$0.73−$0.43−$0.72−$0.72−$0.79
Surprise−51.3%+2.5%+10.8%+11.0%−4.7%−6.0%−6.0%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported————$20.0M——Pending
Estimate—$3.1M—$375.0K$10.6M$2.9M$2.9M$333.3K
Surprise————+88.2%———
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.79 | — | — |
| Aug 2026 | −$0.72 | −$0.76 | −6.0% |
| Aug 2026 | −$0.72 | −$0.76 | −6.0% |
| May 2026 | −$0.43 | −$0.45 | −4.7% |
| Mar 2026 | −$0.73 | −$0.65 | +11.0% |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Sep 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.79 | — | — | $333.3K | — | — | — |
| Aug 12, 2026 | −$0.72 | −$0.76 | −6.0% | $2.9M | — | — | +0.5% |
| Aug 11, 2026 | −$0.72 | −$0.76 | −6.0% | $2.9M | — | — | +0.8% |
| May 12, 2026 | −$0.43 | −$0.45 | −4.7% | $10.6M | $20.0M | +88.2% | +4.6% |
| Mar 25, 2026 | −$0.73 | −$0.65 | +11.0% | $375.0K | — | — | −0.1% |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | |||||||
| Nov 6, 2025 | |||||||
| Aug 12, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 31, 2025 | |||||||
| Sep 30, 2024 | |||||||
| Jun 30, 2024 | |||||||
| Mar 31, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Sep 30, 2023 | |||||||